Difference between revisions of "Avapritinib (Ayvakit)"
m |
|||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Gastrointestinal stromal tumor]] | *[[Gastrointestinal stromal tumor]] | ||
| + | *[[Systemic mastocytosis]] | ||
== Patient Drug Information== | == Patient Drug Information== | ||
| Line 14: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*1/9/2020: Initial approval for adults with unresectable or metastatic [[Gastrointestinal stromal tumor|gastrointestinal stromal tumor (GIST)]] harboring a [[Biomarkers#PDGFRA|platelet-derived growth factor receptor alpha (PDGFRA)]] [[Biomarkers#Exon_18|exon 18]] [[Biomarkers#Alterations|mutation]], including [[Biomarkers#D842V|D842V mutations]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02508532 NAVIGATOR])'' | *1/9/2020: Initial approval for adults with unresectable or metastatic [[Gastrointestinal stromal tumor|gastrointestinal stromal tumor (GIST)]] harboring a [[Biomarkers#PDGFRA|platelet-derived growth factor receptor alpha (PDGFRA)]] [[Biomarkers#Exon_18|exon 18]] [[Biomarkers#Alterations|mutation]], including [[Biomarkers#D842V|D842V mutations]]. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT02508532 NAVIGATOR])'' | ||
| + | *6/16/2021: Approved for adult patients with advanced [[systemic mastocytosis]] (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ''(Based on EXPLORER and PATHFINDER)'' | ||
==Also known as== | ==Also known as== | ||
| Line 31: | Line 33: | ||
[[Category:Gastrointestinal stromal tumor medications]] | [[Category:Gastrointestinal stromal tumor medications]] | ||
| + | [[Category:Systemic mastocytosis medications]] | ||
[[Category:FDA approved in 2020]] | [[Category:FDA approved in 2020]] | ||
Revision as of 00:41, 18 June 2021
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable inhibitor of specific mutated forms of platelet-derived growth factor receptor alpha (PDGFR alpha; PDGFRa) and mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, avapritinib specifically binds to and inhibits specific mutant forms of PDGFRa and c-Kit, including the PDGFRa D842V mutant and various KIT exon 17 mutants. This results in the inhibition of PDGFRa- and c-Kit-mediated signal transduction pathways and the inhibition of proliferation in tumor cells that express these PDGFRa and c-Kit mutants.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient Drug Information
History of changes in FDA indication
- 1/9/2020: Initial approval for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations. (Based on NAVIGATOR)
- 6/16/2021: Approved for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). (Based on EXPLORER and PATHFINDER)
Also known as
- Code name: BLU-285
- Brand name: Ayvakit